According to the results of a phase II study involving 37 patients, the tyrosine kinase inhibitor pazopanib (Votrient), a treatment for renal cell carcinoma, showed some anti-cancer activity in certain patients with thyroid cancer and may offer a new therapeutic option.
Of the 37 patients, 49% had a partial response (PR), while it was determined that 66% of them would see that response sustained for at least a year.
However, researchers noted that side effects were common and dose adjustment was necessary in several patients. Further studies would be necessary to truly determine efficacy in this patient population.
CANCER TYPE(S)
Radioiodine-refractory, progressive differentiated thyroid cancer
TREATMENT TYPE(S)
Tyrosine kinase inhibitor
WHERE WAS THIS STUDY PUBLISHED?
The Lancet Oncology
Source(s)
MedPageToday
Bible K et al "Efficacy of pazopanib in progressive, radioiodine-refractory metastatic differentiated thyroid cancers: results of a phase 2 consortium study." Lancet Oncol 2010; DOI: 10.1016/S1470-2045(10)70203-5.
The information provided on CancerTreatment.net is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of CancerTreatment.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
